La interrupción precoz del tratamiento triple con telaprevir de la hepatitis crónica C por efecto adverso grave no presupone necesariamente el fracaso del tratamiento / Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure
Gastroenterol. hepatol. (Ed. impr.)
; 38(2): 78-81, feb. 2015. tab
Article
in Spanish
| IBECS
| ID: ibc-133025
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
No disponible
Full text:
Available
Collection:
National databases
/
Spain
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.3: End transmission of communicable diseases
Database:
IBECS
Main subject:
Antiviral Agents
/
Hepatitis C, Chronic
/
Drug Hypersensitivity
Limits:
Female
/
Humans
/
Male
Language:
Spanish
Journal:
Gastroenterol. hepatol. (Ed. impr.)
Year:
2015
Document type:
Article
Institution/Affiliation country:
Hospital Universitario de Girona «Doctor Josep Trueta»/España